
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is in a strong position for future growth with promising developments in its pipeline, including new diagnostic and therapeutic opportunities. The company's recent financial performance has been impressive, with outperformance in all product segments and a clean earning per share beat. The potential for upcoming catalysts, such as FDA approvals and new partnerships, make this stock an attractive investment opportunity. The company's diversified portfolio and strong partnerships also provide stability and potential for continued growth in the highly competitive healthcare industry.
Bears say
Lantheus Holdings is facing a transitional period with the search for a new CEO, which could lead to potential instability and uncertainty within the company. However, the company's strong product portfolio and solid financials provide some stability and potential growth opportunities in the near future with the launch of PYL TruVu, the re-acceleration of Pylaify and TruVu, and the anticipated re-acceleration of the company's revenue in 2027 after the securement of a new TPT status for TruVu. Overall, the negative outlook on the stock is driven by the potential risks and uncertainties surrounding the CEO search and the transitional period for the company.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares